[Chinese Expert Consensus on the Diagnosis and Treatment of Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation (2024)]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2024 Aug 12

PMID 39134482

Affiliations

Soon will be listed here.

Abstract

Despite the continuous improvement in the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT), acute graft-versus-host disease (GVHD) remains a major complication and cause of death. In recent years, with the emergence of new drugs for the prevention and treatment of acute GVHD and the update of a series of clinical studies, there have been varying degrees of changes in the routine prevention and treatment regimens for acute GVHD. Based on the main research achievements and the accumulation of clinical experience in this field in recent years, this consensus further updates the "The Consensus on Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Diseases in China-Acute Graft-Versus-Host Disease (2020) .

Citing Articles

Umbilical Cord Blood Platelet Lysate Eyedrops for the Treatment of Severe Ocular Surface Disorders in Graft vs. Host Disease Patients: Clinical Study.

Gagliano C, Foti R, Zeppieri M, Maniaci A, Lavalle S, Tancredi G Life (Basel). 2024; 14(10).

PMID: 39459568 PMC: 11509496. DOI: 10.3390/life14101268.

References

Liu J, Gao H, Xu L, Mo X, Liu R, Liang S . Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting Vδ2 T cells activities after hematopoietic transplantation for blood malignancies. J Immunother Cancer. 2020; 8(1). PMC: 7206968. DOI: 10.1136/jitc-2019-000208. View

Wang Y, Wu D, Liu Q, Xu L, Liu K, Zhang X . Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. J Hematol Oncol. 2019; 12(1):88. PMC: 6724335. DOI: 10.1186/s13045-019-0781-y. View

Zhao K, Lin R, Fan Z, Chen X, Wang Y, Huang F . Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. J Hematol Oncol. 2022; 15(1):22. PMC: 8900437. DOI: 10.1186/s13045-022-01240-4. View

Wang L, Kong P, Zhang C, Gao L, Zhu L, Liu J . Outcomes of patients with hematological malignancies who undergo unrelated donor hematopoietic stem cell transplantation with ATG-Fresenius versus ATG-Genzyme. Ann Hematol. 2023; 102(6):1569-1579. PMC: 10182153. DOI: 10.1007/s00277-023-05220-7. View

Shen M, Hong S, Lou R, Chen R, Zhang X, Xu L . A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation. Exp Hematol Oncol. 2022; 11(1):25. PMC: 9067003. DOI: 10.1186/s40164-022-00278-x. View

Yang F, Lu D, Hu Y, Huang X, Huang H, Chen J . Risk Factors for Graft-Versus-Host Disease After Transplantation of Hematopoietic Stem Cells from Unrelated Donors in the China Marrow Donor Program. Ann Transplant. 2017; 22:384-401. PMC: 6248289. DOI: 10.12659/aot.902805. View

Han L, Wang Y, Fan Z, Huang F, Zhou J, Fu Y . Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard-risk acute lymphoblastic leukaemia in first complete remission. Br J Haematol. 2017; 179(1):120-130. DOI: 10.1111/bjh.14854. View

Jagasia M, Greinix H, Arora M, Williams K, Wolff D, Cowen E . National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2014; 21(3):389-401.e1. PMC: 4329079. DOI: 10.1016/j.bbmt.2014.12.001. View

Yu W, Wang Y, Wu D, Liu Q, Xu L, Zhang X . Comparison of efficacy between HLA6/6- and HLA3/6-matched haploidentical hematopoietic stem cell transplant in T-cell-replete transplants between parents and children. Sci China Life Sci. 2018; 62(1):104-111. DOI: 10.1007/s11427-017-9302-1. View

10.

Harris A, Young R, Devine S, Hogan W, Ayuk F, Bunworasate U . International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2015; 22(1):4-10. PMC: 4706482. DOI: 10.1016/j.bbmt.2015.09.001. View

11.

Lai Y, Chen Y, Hu D, Jiang M, Liu Q, Liu L . Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG). J Hematol Oncol. 2014; 7:59. PMC: 4237802. DOI: 10.1186/s13045-014-0059-3. View

12.

Schoemans H, Lee S, Ferrara J, Wolff D, Levine J, Schultz K . EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant. 2018; 53(11):1401-1415. PMC: 6786777. DOI: 10.1038/s41409-018-0204-7. View

13.

Cao L, Huo W, Zhang X, Xu L, Wang Y, Yan C . Peripheral blood stem cell transplantation from haploidentical related donor could achieve satisfactory clinical outcomes for intermediate- or high-risk adult acute myeloid leukemia patients. Bone Marrow Transplant. 2023; 59(2):203-210. DOI: 10.1038/s41409-023-02117-x. View

14.

Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R . Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. N Engl J Med. 2020; 382(19):1800-1810. DOI: 10.1056/NEJMoa1917635. View

15.

Luo Y, Xiao H, Lai X, Shi J, Tan Y, He J . T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. Blood. 2014; 124(17):2735-43. PMC: 4208287. DOI: 10.1182/blood-2014-04-571570. View

16.

Sun Y, Huang X, Xu L, Zhang X, Yan C, Liu K . [Impact of mycophenolate mofetil prophylaxis duration on acute graft-versus-host disease after haploidentical stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2018; 39(4):286-291. PMC: 7342124. DOI: 10.3760/cma.j.issn.0253-2727.2018.04.005. View

17.

Sun W, Ma R, He Y, Bai L, Chen Y, Chen Y . [Clinical analysis of sirolimus as an alternative GVHD prophylaxis for patients with kidney injury undergoing allo-HSCT]. Zhonghua Nei Ke Za Zhi. 2023; 62(12):1444-1450. DOI: 10.3760/cma.j.cn112138-20230306-00136. View

18.

Xu Z, Mo X, Kong Y, Wen Q, Han T, Lyu M . Mini-dose methotrexate combined with methylprednisolone as a first-line treatment for acute graft-versus-host disease: A phase 2 trial. J Transl Int Med. 2023; 11(3):255-264. PMC: 10474881. DOI: 10.2478/jtim-2023-0111. View

19.

Wang Y, Xu L, Liu K, Liu D, Wang J, Chen H . Low-dose MTX combined with low-dose methylprednisolone as a first-line therapy for the treatment of acute GVHD: safety and feasibility. Bone Marrow Transplant. 2010; 46(6):892-8. DOI: 10.1038/bmt.2010.197. View

20.

Zhu P, Yang L, Wu Y, Shi J, Lai X, Liu L . Graft CD8 T-cell-based risk system predicts survival in antithymocyte globulin-based myeloablative haploidentical peripheral blood stem cell transplantation. Clin Transl Immunology. 2024; 13(1):e1484. PMC: 10786671. DOI: 10.1002/cti2.1484. View